Novotalk develops on-demand (asynchronous), self-directed speech and language teletherapy solutions that allow individuals with speech impairments to learn, practice, gain, and maintain intelligible speech remotely, independently, and discreetly.The companys first commercialized product is a patented web and mobile application that provides self-directed speech therapy and training to people who stutter, enabling regular Novotalk users to experience fluent speech.

The first version is in Hebrew and English.Novotalk has signed a joint venture agreement with Mount Sinai Health System in New York for commercialization in North America and future research and development collaborations.

Novotalk is available to patients in Israel in collaboration with Hadassah Medical Center in Jerusalem.